🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 3 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/10/2020 46,86 49,14 46,86 48,93 +4,66% 4,87% 409.500
30/09/2020 47,19 47,88 46,26 46,75 -1,10% 3,43% 258.200
29/09/2020 47,78 48,28 47,24 47,27 -0,88% 2,18% 245.500
28/09/2020 46,89 48,04 46,54 47,69 +2,34% 3,20% 449.600
25/09/2020 46,48 47,80 45,95 46,60 +0,47% 3,98% 524.400
24/09/2020 45,40 46,54 44,34 46,38 +2,14% 4,85% 491.400
23/09/2020 46,24 48,08 45,37 45,41 -1,54% 5,85% 351.400
22/09/2020 45,34 46,30 44,19 46,12 +1,45% 4,66% 421.900
21/09/2020 46,66 47,55 45,16 45,46 -3,73% 5,12% 529.300
18/09/2020 48,08 48,15 46,16 47,22 -0,59% 4,14% 635.300
17/09/2020 46,22 47,85 46,01 47,50 +1,45% 3,98% 459.200
16/09/2020 48,06 48,46 46,60 46,82 -1,62% 3,87% 459.400
15/09/2020 49,11 49,61 47,15 47,59 -2,32% 5,01% 871.300
14/09/2020 46,39 48,86 46,00 48,72 +6,84% 6,17% 593.300
11/09/2020 46,40 46,69 44,77 45,60 -1,45% 4,14% 382.500
10/09/2020 48,35 48,84 46,26 46,27 -3,98% 5,34% 515.000
09/09/2020 48,00 48,75 47,40 48,19 +1,43% 2,81% 419.700
08/09/2020 47,38 48,61 46,86 47,51 -1,02% 3,69% 512.600
04/09/2020 48,76 49,01 46,65 48,00 -1,03% 4,84% 493.300
03/09/2020 50,31 50,79 47,84 48,50 -3,66% 5,86% 475.700
02/09/2020 49,25 50,74 49,03 50,34 +1,70% 3,47% 550.500
01/09/2020 49,49 50,37 48,94 49,50 +0,15% 2,89% 640.200
31/08/2020 49,21 50,45 48,60 49,43 +1,38% 3,76% 584.500
28/08/2020 48,59 48,79 47,79 48,75 +1,08% 2,06% 431.100
27/08/2020 47,95 49,51 47,30 48,23 +0,73% 4,61% 342.100
26/08/2020 50,01 50,22 47,55 47,88 -4,26% 5,35% 395.100
25/08/2020 48,86 50,46 48,20 50,01 +4,10% 4,63% 1.050.400
24/08/2020 48,49 49,06 47,32 48,04 -1,11% 3,59% 466.800
21/08/2020 48,40 48,77 47,98 48,58 +0,23% 1,64% 337.800
20/08/2020 49,11 49,11 47,78 48,47 -1,34% 2,71% 345.900